Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Priority Review Voucher Stories

2012-07-11 02:25:28

SAN DIEGO, July 11, 2012 /PRNewswire/ -- This week the Food and Drug Administration Safety and Innovation Act (Act) was signed into law. The Act amends the Federal Food, Drug, and Cosmetic Act in a variety of ways that encourage or facilitate the development of drugs for patients with rare diseases, including: Establishment of a Rare Pediatric Disease Priority Review Voucher Incentive Program. Entitles the sponsor of a "rare pediatric disease application" to a "priority review voucher"...

2012-07-09 14:23:13

Approval Culminates Years of Advocacy, Education and Relationship Building Led by NORD WASHINGTON, July 9, 2012 /PRNewswire-USNewswire/ -- Signed by President Obama today, the U.S. Food and Drug Administration (FDA) Safety and Innovation Act includes the most groundbreaking measures for rare disease patients and their families since the Orphan Drug Act of 1983. As the long-standing and recognized policy leader and advocate for the rare disease community, the National Organization for...

2012-06-26 14:21:29

WASHINGTON, June 26, 2012 /PRNewswire-USNewswire/ -- Millions of Americans who have serious rare diseases and no treatment may face a brighter future as a result of a bill approved today by the U.S. Senate, according to the National Organization for Rare Disorders (NORD). (Logo: http://photos.prnewswire.com/prnh/20110719/DC37656LOGO-b) "We salute the Senate for decisive and bipartisan action in approving the FDA Safety and Innovation Act (S. 3187)," said Peter L. Saltonstall, president and...

2008-08-26 09:00:28

VioQuest Pharmaceuticals (OTCBB: VOQP) today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta(TM) (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases. "Based on Lenocta's demonstrated...

2006-03-08 08:30:00

By Maggie Fox, Health and Science Correspondent WASHINGTON -- Companies that develop drugs to treat diseases of poor countries such as malaria should be rewarded with vouchers that might speed up government review of far more lucrative drugs, researchers proposed on Tuesday. Another set of researchers suggested that rich countries subsidize the use of the most effective drugs to fight malaria in poorer nations. Both reports, published in the journal Health Affairs, are aimed at finding ways...